PLoS ONE (Jan 2021)

Trends in extent of surgical cytoreduction for patients with ovarian cancer

  • Deanna H. Wong,
  • Alexandra L. Mardock,
  • Erica N. Manrriquez,
  • Tiffany S. Lai,
  • Yas Sanaiha,
  • Abdulrahman K. Sinno,
  • Peyman Benharash,
  • Joshua G. Cohen

Journal volume & issue
Vol. 16, no. 12

Abstract

Read online

Purpose To identify patient and hospital characteristics associated with extended surgical cytoreduction in the treatment of ovarian cancer. Methods A retrospective analysis using the National Inpatient Sample (NIS) database identified women hospitalized for surgery to remove an ovarian malignancy between 2013 and 2017. Extended cytoreduction (ECR) was defined as surgery involving the bowel, liver, diaphragm, bladder, stomach, or spleen. Chi-square and logistic regression were used to analyze patient and hospital demographics related to ECR, and trends were assessed using the Cochran-Armitage test. Results Of the estimated 79,400 patients undergoing ovarian cancer surgery, 22% received ECR. Decreased adjusted odds of ECR were found in patients with lower Elixhauser Comorbidity Index (ECI) scores (OR 0.61, pConclusions Likelihood of ECR was associated with increased medical comorbidity complexity, higher income, and undergoing the procedure at high surgical volume hospitals. The proportion of ovarian cancer cases with ECR has decreased from 2013–17, with more cases performed at high surgical volume hospitals.